Description Of Risk Factors Associated With The Incident Of Urinary Tract Infections In Pregnant Women
Keywords:
Risk Factors, Urinary Tract Infection (UTI), Pregnancy.Abstract
Throughout the world, infectious diseases are a problem that affects both developed and developing countries. After lung infections, urinary tract infections rank as the second most common health problem. Anatomically, women are more likely than men to experience urinary tract infections due to the shorter urethra in women. Pregnant women's bodies undergo structural and physiological changes that increase their chances of developing urinary tract infections. In pregnant women alone, there is a 20% incidence of urinary tract infections (UTI). Literature review with narrative review design.The results obtained were that pregnant women were more at risk of developing UTIs.Oobesity, multiparity, holding back urination, sexual relations and individual hygiene are some of the risk factors that will occurcan increase the risk of a more serious UTI.
References
Jeschke, M.G. et al. Burn injuries. Nat Rev Dis Primers 6, (2020).
Altintas, MA & Vogt, PM Burn injuries. in General Trauma Care and Related Aspects: Trauma Surgery II 169–176 (Springer Berlin Heidelberg, 2014). doi:10.1007/978-3-540-88124-7_13.
Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256-266. [PubMed]
Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009 Mar 15;48(6):787-94. [PMC free article] [PubMed]
Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000 Nov 25;356(9244):1800-5. [PubMed]
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. [PMC free article] [PubMed]
Diaz RS, Hunter JR, Camargo M, Dias D, Galinskas J, Nassar I, de Lima IB, Caldeira DB, Sucupira MC, Schechter M. Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil. BMC Infect Dis. 2023 May 24;23(1):347. [PMC free article] [PubMed]
DeKoven S, Naccarato M, Brumme CJ, Tan DHS. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series. HIV Med. 2023 Nov;24(11):1137-1143. [PubMed]
Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW, Richman DD. 2022 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2022 Oct;30(4):559-574. [PMC free article] [PubMed]
Sutrasno MA, Yulia N, Rumana NA, Fannya P. Literature review gambaran karakteristik pasien HIV/AIDS di fasilitas pelayanan kesehatan di Indonesia. Jurnal Manajemen Informasi dan Administrasi Kesehatan. (2022) 5:56–65. [Google Scholar]
